ArticleCureus2025
Comparative Study of Glycemic Control and Treatment Satisfaction in Patients With Type 1 Diabetes on Sensor-Augmented Insulin Pump, Insulin Pump, and Multiple Daily Insulin Injections: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with type 1 diabetes mellitus (T1DM) depend on lifelong insulin therapy. In recent decades, advances in diabetes technology have introduced insulin pumps and continuous glucose monitoring (CGM) systems, offering new approaches to disease management. Despite these innovations, evidence regarding their impact on glycemic control and patient satisfaction within the Saudi population remains scarce. This gap is important, as cultural, lifestyle, and genetic factors may influence treatment outcomes. PATIENTS AND
methodsA cross-sectional study was conducted at the Endocrine Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia. Eligible participants were patients aged 14 years and older with T1DM who had been on one of the following regimens for at least six months: a sensor-augmented insulin pump (MiniMed 640G or 740G, Medtronic, Dublin, Ireland), an insulin pump without a sensor (Paradigm VEO 754, Medtronic), or multiple daily insulin injections (MDIs).
resultsThe study enrolled 196 patients, the majority of whom were female (76.5%), with ages ranging from 14 to 55 years. Over half of the cohort (52.5%) were treated with MDI, while 25% and 8.2% used sensor-augmented pumps and non-sensor pumps, respectively. Regression analyses demonstrated that patients using sensor-augmented pumps achieved significantly lower glycosylated hemoglobin (HbA1c) levels compared to those treated with MDI. In addition, sensor-augmented pump users reported markedly higher satisfaction scores. The frequency of educator visits explained approximately 20% of the variability in satisfaction (R² = 0.202).
conclusionsSensor-augmented insulin pumps provide superior outcomes compared with MDIs in patients with T1DM, offering both improved glycemic control and greater patient satisfaction. These findings underscore the importance of integrating advanced technologies into diabetes care, particularly in populations with unique cultural and lifestyle characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.